Abstract:Abstract Purpose Age at breast cancer diagnosis not only predicts clinical outcome, but also indicates distinct molecular features thus we can choose the most appropriate treatment strategies. Yet little is known about the molecular profile of young and elderly triple negative breast cancers (TNBCs). Methods Clinical, genomic and transcriptome features of young (<40 year-olds) and elderly (≥65 year-olds) TNBC patients were studied in a cohort of 473 TNBCs from Fudan University Shanghai Cancer Center. Results In this study, 50, 354 and 69 patients were <40, 40–64 and ≥65 years of age, respectively. Young TNBCs had more relapse or metastasis within the first 2 years after surgery (P=0.036) which was also significant in the basal-like subgroup (P=0.004), while elderly TNBCs were more likely to be luminal androgen receptor (LAR) subtype (46%) harboring frequent PIK3CA and KMT2C/KMT2D somatic mutations, with more fibrosis or mesenchymal-like (MES) subtype (in the basal-like subgroup) and featured by significantly lower Ki-67 index. Gene set enrichment analyses revealed that young TNBCs showed elevated expression of genes involved in cell cycle, nucleotide metabolism and DNA damage repair. In further discussion on nucleotide metabolism, TYMS, a crucial gene encoding thymidylate synthase while is also the target of fluorouracil and capecitabine, were identified to be enriched in young TNBCs independent of molecular subtype in both our cohort (adjusted P<0.001) and METABRIC (adjusted P=0.027). We next studied DNA damage features and found that while TNBCs of different age groups had comparable somatic mutation load, their mutations had distinct generation mechanism that homologous recombination deficiency (HRD) related signature and Aging related signature tend to be enriched in younger and elder patients, respectively. We also observed higher germline BRCA1 mutation rate in young TNBCs (23%). Interestingly, while germline BRCA2 mutation rate was comparable among the groups, copy number (CN) loss of Chr13q13 (with BRCA2 in the 'peak') was almost exclusively found in young patients (adjusted P<0.05). We also found enriched CN loss at Chr15q13 (with FAN1 in the 'peak') and CN amplification at Chr1p34 (with KDM4A in the 'peak') in young patients. These two events significantly affected the expression levels of FAN1 and KDM4A, respectively, and were both corrected with genomic based HRD indexes. Conclusions TNBCs of different age had distinct clinical and molecular features. We should pay attention to that nearly half of the TNBCs diagnosed at 65 years-old or later were not basal-like cancers but a special group with positive AR staining. Taking together with the higher fibrosis/MES proportion in elderly TNBC, we should reconsider the benefit of specific treatment strategies (like neoadjuvant chemotherapy) in these patients. The young TNBCs were characterized by activated cell cycle, elevated nucleotide metabolism (especially TYMS expression and corresponding pyrimidine metabolism) and enhanced DNA damage (especially HRD). These molecular features supported the aggressive phenotypes of young TNBC, while also provide us with potential therapeutic strategies. Citation Format: Ma D, Jiang Y-Z, Xie M-D, Xiao Y, Zhao S, Shao Z-M. Multi-omics profiling reveals distinct molecular features in young and elderly triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-08-11.

Separate and combined effects of advanced age and obesity on mammary adipose inflammation, immunosuppression and tumor progression in mouse models of triple negative breast cancer

Abstract C016: Age dictates immune response within the tumor microenvironment of triple negative breast cancer

Abstract 6969: Determining the role of obesity in breast cancer progression

Abstract 6870: Immunological aging in triple negative breast cancer leads to a chronic interferon phenotype and immune cell exhaustion that impedes response to therapy

Abstract LB-183: Anti-PD1 Blunts Obesity Associated Triple Negative Breast Cancer Progression

Abstract 5122: Obesity Promotes Tumor Growth, Reduces Breast Tumor Latency and Correlates with Neovascularization

Alterations in the mammary gland and tumor microenvironment of formerly obese mice

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women

Abstract A011: Assessing pro-tumorigenicity of the aging microenvironment in a murine ovarian cancer model

Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model

Abstract PO1-14-06: Integrated analysis reveals the impact of obesity on triple-negative breast cancer

Abstract 2645: Obesity Promotes Tumor Growth, Reduces Breast Tumor Latency and Correlates with Neovascularization: Therapeutic and Diagnostic Implications

Development and Characterization of Syngeneic Orthotopic Transplant Models of Obesity-Responsive Triple-Negative Breast Cancer in C57BL/6J Mice

Abstract 288: Middle-aged murine models of triple negative breast cancer (TNBC) show significant differences in tumor immune and stromal environments when compared to classic 6-8 week old models; Challenges and opportunities for preclinical efficacy studies

Mammary adipocytes promote breast tumor cell invasion and angiogenesis in the context of menopause and obesity

Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue.

Obesity Promotes Cooperation of Cancer Stem-Like Cells and Macrophages to Enhance Mammary Tumor Angiogenesis

Escape from breast tumor dormancy: The convergence of obesity and menopause

Abstract P3-08-11: Multi-omics Profiling Reveals Distinct Molecular Features in Young and Elderly Triple Negative Breast Cancer

Abstract TMEM-029: AGING INCREASES SUSCEPTIBILITY TO OVARIAN CANCER METASTASIS IN A MURINE ALLOGRAFT MODEL

Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies